Most gastrointestinal stromal tumors (GISTs) express oncogenic and constitutively active forms of the KIT or platelet-derived growth factor receptor alpha (PDGFRA) receptor tyrosine kinase proteins, and these kinase oncoproteins serve as targets for effective therapies. Given that mutant KIT oncoproteins serve crucial transforming roles in GISTs, we evaluated interactions with the KIT oncoproteins and determined signaling pathways that are dependent on KIT oncogenic activation in GISTs. Tyrosine-phosphorylated KIT oncoproteins interacted with PDGFRA, PDGFRB, phosphatidylinositol 3-kinase (PI3-K) and PKCh in GIST cells, and these interactions were abolished by KIT inhibition with imatinib or PKC412 or KIT RNAi. Notably, tyrosine-phosphorylated PDGFRA was prominent in frozen GIST tumors expressing KIT oncoproteins, suggesting that KIT-mediated PDGFRA phosphorylation is an efficient and biologically consequential mechanism in GISTs. Activated signaling intermediates were identified by immunoaffinity purification of tyrosine-phosphorylated proteins in GIST cells before and after treatment with KIT inhibitors, and these analyses show that GRB2, SHC, CBL and MAPK activation are largely KIT dependent in GISTs, whereas PI3-K, STAT1 and STAT3 activation are partially KIT dependent. In addition, we found that phosphorylation of several tyrosine kinase proteins -including JAK1 and EPHA4 -did not depend on KIT activation. Likewise, paxillin activation was independent of the KIT oncogenic signal. These studies identify signaling pathways that can provide both KIT-dependent and KIT-independent therapeutic synergies in GIST, and thereby highlight clinical strategies that might consolidate GIST therapeutic response to KIT/PDGFRA inhibition.
Introduction
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the digestive tract. GIST cells share morphological and immunophenotypic features -including expression of the KIT receptor tyrosine kinase (RTK) -with interstitial cells of Cajal (ICC), which are the pacemaker cells responsible for coordinating gastrointestinal peristaltic activity (Heinrich et al., 2002) . Most GISTs (85%) contain gain-offunction KIT oncogenic mutations, which are associated with constitutive KIT tyrosine phosphorylation, and activation of cell proliferation and survival signaling pathways (Duensing et al., 2004b) . Alternately, a small subset of GISTs has oncogenic mutations in the gene encoding platelet-derived growth factor receptor alpha (PDGFRA) that confer constitutive activation (Heinrich et al., 2003; Hirota et al., 2003) . Although KIT and PDGFRA oncogenic mutations are mutually exclusive in GISTs, approximately 30% of KIT-mutant GISTs express PDGFRA strongly (Heinrich et al., 2003) . Notably, the oncogenic KIT and PDGFRA mutations can be targeted effectively with imatinib mesylate (Gleevec) in GIST cell culture models and in more than 80% of GIST patients (Tuveson et al., 2001; Demetri et al., 2002; Verweij et al., 2004) .
KIT is a member of the PDGFR subfamily of RTK proteins, which feature extracellular Ig domains and a split kinase domain (Heinrich et al., 2002) . KIT undergoes homodimerization and autophosphorylation when bound by the ligand, stem cell factor, or when activated by oncogenic mutations (Hirota et al., 1998; Rubin et al., 2001) . In addition, KIT can heterodimerize with the PDGFR family members FLT3 (Otto et al., 2001) and PDGFRA (Hirota et al., 2003) , and presumably with other RTKs. Therefore, the clinical success of KIT inhibitors in patients with GIST might result from inactivation of KIT downstream signaling pathways and KIT heterodimerization partners.
Although most GIST patients have dramatic therapeutic responses to imatinib, some patients are resistant to imatinib, and very few patients exhibit a complete response to this drug (Demetri et al., 2002) . The aim of the studies reported herein was to evaluate cell signaling pathways transmitting proliferation and survival signals from KIT, and to determine which signaling intermedi-ates are dependent on KIT activation in GIST. These studies, performed in human GIST cell lines before and after treatment with KIT inhibitors, interrogated signaling proteins that play key roles in tyrosine kinase-mediated cell proliferation, survival and adhesion. Mechanisms of oncogenic signaling pathway activation were evaluated further by determining KIT interactions with various kinase and adaptor proteins. These studies show that certain signaling intermediates are largely KIT dependent in GISTs, whereas others are not. These insights will be helpful in designing rational combination-targeted therapy strategies in GIST.
Results

KIT interactions in primary GISTs
Kinase protein interactions with oncogenic KIT were evaluated in two untreated GIST specimens with heterozygous KIT exon 11 (GIST3) or exon 9 (GIST4) mutations (Figure 1 ). GIST3 and GIST4 lacked PDGFRA gene mutations (data not shown), but expressed phosphorylated PDGFRA in addition to constitutively phosphorylated KIT (Figure 1 ). Phosphatidylinositol 3-kinase (PI3-K) p85 immunoprecipitates revealed a dominant 170/ 160 kD tyrosine-phosphorylated doublet in both GISTs (Figure 1 ), consistent in size with the transmembrane forms of PDGFRA (170 kD) and KIT (160 kD). PI3-K p85 interactions with KIT and PDGFRA were confirmed by immunostaining (Figure 1 ). These findings suggest that KIT and PDGFRA were the predominant activated RTKs in GIST3 and GIST4. In addition, interaction between PDGFRA and the mature form of KIT was evident in the PDGFRA immunoprecipitations (Figure 1 ). Because KIT and PDGFRA are structurally similar RTKs, the possibility of a spurious coimmunoprecipitation, resulting from direct binding of KIT by the PDGFRA antiserum, was evaluated. This possibility was excluded using a KIT-mutant GIST that expressed KIT strongly but lacked PDGFRA expression: KIT was not detected in the PDGFRA immunoprecipitations from this GIST (data not shown). ABL was not demonstrably phosphorylated, and was not complexed with KIT, in GIST3 or GIST4 (Figure 1 ). In sum, these findings demonstrate interactions between KIT, PDGFRA and PI3-K p85, and suggest that ABL -despite the precedent for interaction with KIT in human leukemias (Hallek et al., 1996) -neither complexes substantially with KIT nor is demonstrably activated in GIST.
Kinase expression varies in GIST cell lines Variability of key kinase expression was evaluated by immunoblotting in the GIST882, GIST48 and GIST430 cell lines. KIT, PI3-K p85 and PKCy were expressed at similar levels in each of these lines, whereas PDGFRA, PDGFRB and ABL expression varied considerably, being strongest in GIST882, GIST48 and GIST430, respectively (Figure 2 ).
Kinase interactions in imatinib-sensitive and imatinibresistant GIST cell lines Kinase activation and interactions were evaluated in the GIST882 and GIST48 cell lines. Kinase interactions in these cell lines were evaluated before and after pharmacologic inhibition of KIT/PDGFR by imatinib in GIST882 (Figure 3 ) and PKC412 in the imatinibresistant GIST48 (Figure 4 ). Wild-type PDGFRA and PDGFRB were phosphorylated and coprecipitated with oncogenic KIT (Figures 3a and 4a ), suggesting that Figure 1 KIT-dependent kinase interactions in primary, frozen, GISTs. Internal standards are frozen GISTs, GIST1 (KIT mutant) and GIST2 (PDGFRA mutant), which express high levels of KIT and PDGFRA, respectively. GIST3 (a) and GIST4 (b) each contain KIT mutations: the first three lanes in each panel are total cell lysates, whereas the remaining four lanes are immunoprecipitates of KIT (Santa Cruz, sc-168), PDGFRA (Santa Cruz, sc-338), ABL (Santa Cruz, sc-131) and PI3-K p85 (Upstate, Lake Placid, NY, USA, 06-497), evaluating kinase activation and interactions. The PY99 immunostain shows KIT and PDGFRA activation, and suggests that activated KIT and PDGFRA are complexed with PI3-K p85. KIT complexing with PDGFRA and PI3-K p85 is confirmed by the KIT immunostains of PDGFRA and PI3-K p85 immunoprecipitates, respectively. PI3-K p85 complexing with KIT and PDGFRA, but not ABL, is also shown by the PI3-K immunostains of KIT, PDGFRA and ABL immunoprecipitates, respectively.
PDGFRs heterodimerize with, and are cross-phosphorylated by, the constitutively activated KIT mutants in GIST882 and GIST48. KIT inactivation inhibited the complexing between KIT and PDGFR (Figures 3b and  4b ). PI3-K p85 and p110a, and PKCy also complexed with oncogenic KIT, as shown best in the KIT and PKCy immunoprecipitates, respectively, and as for PDGFR, these interactions were partially inhibited by imatinib (Figures 3 and 4) . Likewise, PI3-K p85 interactions with PKCy were inhibited by imatinib (Figures 3b and 4b) . The interaction between KIT and PKCy appeared to be relatively weak, being most convincing in the GIST882 cells. Interestingly, ABL phosphorylation and interactions between KIT and ABL were not detectable in either GIST882 or GIST48 (Figures 3 and 4) .
KIT-dependent signaling in GIST cell lines Expression of activated signaling intermediates was evaluated by immunoblotting in phosphotyrosine immunopurifications from confluent GIST882 and GIST48 cell lines. The rationale for evaluating signaling intermediates in confluent cells was to highlight activation events that might be strictly dependent on the KIT oncogenic signal, irrespective of whether the cells were actively proliferating. KIT dependence was determined by comparing expression of each protein before and after KIT/PDGFR inhibition by imatinib (in GIST882 cells) and PKC412 (in GIST48 cells). Phosphorylation patterns differed between GIST882 and GIST48, as can be seen by comparing protein expression ratios in the input (total protein) and phosphotyrosine eluate (activated protein) lanes ( Figure 5) . For example, GRB2, FAK and PDGFRA were more strongly phosphorylated -on a per molecule basis -in GIST882 than in GIST48 ( Figure 5 ). However, KIT, PI3-K p85, PI3-K p110a and SHC were strongly tyrosine phosphorylated in both cell lines ( Figure 5 ). In addition, there were substantial similarities between GIST882 and GIST48 with respect to which of the protein activation events were KIT/PDGFR dependent. PI3-K p85, PI3-K p110a, GRB2 and SHC tyrosine phosphorylation were substantially KIT/PDGFR dependent in both cell lines, whereas SRC-family kinases and FAK were minimally KIT/PDGFR dependent in GIST882, and KIT/ PDGFR independent in GIST48 ( Figure 5 ). Weak, partially KIT dependent, tyrosine phosphorylation was demonstrated for STAT1 (GIST48 only), STAT3, JAK2, ABL (GIST48 only), MAPK (GIST882 only), PKCy, CBL (GIST882 only) and HSP90. Weak, KIT independent, tyrosine phosphorylation was demonstrated for EPHA4, JAK1 and paxillin. However, the SRC-family kinase data do not exclude the possibility of functional alterations, in that shifts from SFK c-terminal inhibitory tyrosine phosphorylation to internal activating tyrosine phosphorylation can occur without substantially changing the net phosphorylation levels. The weakly activated wild-type PDGFRB in GIST48 was inhibited by PKC412, and the strongly activated PDGFRA in GIST882 was inhibited by imatinib ( Figure 5 ). These findings are in keeping with the immunoprecipitation studies (Figure 3 ), and suggest that PKC412 or imatinib-mediated PDGFR inhibition results both from direct effects and inactivation of heterodimerized KIT oncoproteins. It is particularly notable that PKCy tyrosine phosphorylation was inhibited by imatinib (GIST882) and PKC412 (GIST48), which is in keeping with KIT-dependent activation of this characteristic GIST kinase (Duensing et al., 2004a) .
Density-dependent effects on signaling protein activation
The density (% confluence) of cancer cell lines, when grown as monolayers in vitro, has been shown to impact phosphorylation of STATs and other signaling proteins (Vultur et al., 2004) . In order to determine whether GIST cell density impacts KIT-dependent signaling, we compared phosphoprotein expression, with and without KIT inhibitor treatment, in 100% confluent ('confluent') vs 75% confluent ('subconfluent') GIST48 cells. These studies were performed in phosphotyrosine immunoaffinity-purified fractions from the GIST cells, and showed that PI3-K p85, FAK and paxillin phosphorylation were substantially increased in 75% confluent cells, compared to 100% confluent cells (Figure 6a and b) . Indeed, FAK phosphorylation was tenfold higher in the 75% confluent cells than in 100% confluent cells (Figure 6b ). The FAK cell density effects were independent of KIT activation, in that FAK remained strongly phosphorylated Figure 2 Kinase expression in GIST cell lines with KIT oncogenic mutations. KIT, PI3-K p85 and PKCy were expressed at similar levels in each of these lines, whereas PDGFRA, PDGFRB and ABL expression varied considerably, being strongest in GIST882, GIST48 and GIST430, respectively. in subconfluent GIST48 after PKC412 treatment. By contrast, the accentuated PI3-K p85 and paxillin phosphorylation in 75% confluent GIST48 was KIT dependent, as shown after PKC412-mediated KIT inactivation, which reduced the phosphoprotein expression to levels found in the 100% confluent GIST48 (Figure 6a and b) . These studies were corroborated, in total cell lysates of GIST48 at four different cell densities, showing stronger FAK Y397 and paxillin Y118 phosphorylation at lower cell density (Figure 6c ). CBL and PKCy were also more strongly phosphorylated -and in a KIT-dependent manner -at 75% confluence, whereas PI3-K p110a and JAK1 were more strongly phosphorylated in 100% confluent cells ( Figure  6a and b) . STAT, JAK2 and HSP90 tyrosine phosphorylation were unaffected by GIST48 cell density (Figure 6a and b).
Preferential interactions with the mature form of KIT Interactions with the two major KIT forms (migrating, in relationship to the molecular size markers in this study, at 160 and 145 kD, but also described traditionally as migrating at 145 and 125 kD) were evaluated in immunoprecipitations with KIT antibody recognizing only the smaller, immature, cytoplasmic, KIT form (KIT N-terminal polyclonal rabbit antibody, Santa Cruz, Santa Cruz, CA, USA, sc-5535) or both KIT forms (mouse monoclonal antibody, Santa Cruz, sc-13508). These studies show that PDGFRA, PI3-K and GRB2 complex preferentially with mature KIT (Figure 7) . Interestingly, both immature and mature KIT coimmunoprecipitated with PI3-K and PKCy, whereas only the mature forms of KIT and PDGFRA coimmunoprecipitated (Figures 1, 3a and 7) . These findings suggest that the cytoplasmic PI3-K and PKCy proteins might modulate all forms of KIT signaling, whereas PDGFRA primarily modulates mature KIT signaling.
KIT RNAi corroboration of small molecule KIT-inhibitor assays Because imatinib and PKC412 are multikinase inhibitors, and therefore not specific for KIT, we used KIT RNAi methods to confirm key findings from the studies (described above) on KIT-dependent GIST cell signaling mechanisms. KIT knockdown was accomplished by infecting GIST882 cells with lentiviral shRNA vectors, and corroborated that PI3-K p85 and CBL activation were KIT dependent (Figure 8a ). KIT-mediated activation of PDGFRA was evaluated by PDGFRA immunostaining of anti-phosphotyrosine immunoprecipitates ( Figure 8a ) and by phosphotyrosine immunostaining of PDGFRA immunoprecipitates (Figure 8b ), and both of these studies showed decreased PDGFRA activation after shRNA KIT knockdown. Thus, these findings are consistent with oncogenic KIT-mediated PDGFRA cross-activation in GIST cells.
Discussion
KIT and PDGFRA mutational activation events are mutually exclusive in GISTs, but these alternate oncogenic tyrosine kinase mechanisms have similar biologic and transforming consequences (Heinrich et al., 2003) . Although KIT expression is a diagnostic hallmark of the majority of GIST cells, the small subset of GISTs with PDGFRA oncoproteins feature uncharacteristically low -and even undetectable -KIT expression (Heinrich et al., 2003; Medeiros et al., 2004) . On the other hand, approximately 30% of KITmutant GISTs express wild-type PDGFRA at high levels, comparable to those in PDGFRA-mutant GISTs (Heinrich et al., 2003) . Previous studies demonstrate that PDGFRA oncoproteins expressed by transfected PDGFRA mutants in vitro can bind with and crossactivate wild-type KIT (Hirota et al., 2003) . Herein, we demonstrate interactions and evidence for cross-activation between oncogenic KIT and wild-type PDGFRA proteins in human GIST tissues. Complexing between KIT and PDGFRA was shown in frozen samples of primary human GISTs as well as in the GIST882 cell line (Figures 1 and 3) . The KIT and PDGFRA complexes were dependent on activation of the KIT oncoproteins, as evidenced by disruption of the complexes after GIST882 exposure to imatinib (Figure 3 ). In addition, the studies in frozen primary GISTs shed light on the nature of KIT oncogenic signaling complexes in untreated GISTs, and reveal that another known imatinib target -PDGFRA -complexes with and is likely coactivated by KIT oncoproteins in GIST. These findings were confirmed by KIT RNAi knockdown assays, in which KIT shRNA-mediated inhibition resulted in decreased PDGFRA activation (Figure 8 ), underscoring that PDGFRA cross-activation can be mediated by KIT oncoproteins in GISTs. These studies show how the KIT oncogenic signal can be amplified to involve other RTKs in GIST, and suggest that imatinib therapeutic efficacy might be based, in part, on inhibition of both the KIT oncoprotein and heterodimerization (PDGFRA) partners.
Interestingly, the interactions between KIT and PDGFRA involved predominantly the mature, transmembrane forms of these kinases (Figures 1 and 7) . Therefore, KIT:PDGFRA interactions, in GIST, likely result from heterodimerization -or other complexingat the cell surface, with resultant activation of canonical RTK signaling cascades. The GIST882 kinase interaction studies, performed in confluent cultures, demonstrate KIT:PDGFRA interactions under basal unstimulated conditions in GIST. Similarly, our studies revealed weak associations between KIT and PDGFRB in GIST (Figures 3 and 4) . However, our studies do not show interactions between ABL and KIT, and nor was ABL demonstrably activated in the GIST frozen tumors and cell lines (Figures 1, 3 and 5 ). These findings suggest that ABL, although a classical imatinib target and a KIT-interacting protein in hematological models (Hallek et al., 1996) , does not modulate or enhance the KIT oncogenic signal in GISTs.
PI3-K pathways play crucial roles in transmitting survival and proliferation signals from various RTK oncoproteins (Herbst et al., 1995; Sordella et al., 2004) . In addition, multiprotein complexes involving KIT, PI3-K and PDGFRB have been demonstrated after transfection of KIT and PDGFRB constructs in 293 Figure 5 (a-d) KIT/PDGFR-dependent activation of kinase signaling proteins in GIST882 (with and without KIT/PDGFR inhibition by imatinib) and GIST48 (with and without KIT/PDGFR inhibition by PKC412). Total cell lysates (lanes 1 and 4 in each blot) and tyrosine-phosphorylated proteins immunoaffinity purified from the cell lysates (lanes 2 and 3 in each blot) were immunostained with antibodies (specified in Materials and methods) to evaluate KIT-dependent activation of various signaling proteins. KIT activation (large arrows in PY99 stains) was substantially suppressed after inhibitor treatment in both cell lines, as was PDGFR activation. Treatment-mediated KIT/PDGFR inhibition was accompanied by dephosphorylation of PI3-K p85, PI3-K p110a, GRB2, SHC, PKCy, STATs, MAPK, CBL and HSP90. cells (Herbst et al., 1995) . In the present studies, the p85 regulatory and p110 catalytic PI3-K subunits were constitutively associated with activated KIT and PDG-FRA in GIST frozen tumors and cell lines (Figures 1, 3  and 7) . These associations were largely abrogated after KIT inhibition by imatinib or PKC412 (Figures 3b and  4b ). PI3-K activation was partially KIT dependent ( Figures 5 and 6 ) and was regulated by cell density (Figure 6 ).
To characterize KIT/PDGFR-dependent signaling pathways in GISTs, we used an efficient phosphotyrosine eluate approach combining phosphotyrosine affinity purification with KIT kinase inhibition in cell lines GIST882 and GIST48. This approach enabled efficient immunoblot evaluations of KIT/PDGFRdependent tyrosine phosphorylation in a panel of signaling intermediates, in a single immunoblotting experiment. KIT was inhibited by imatinib treatment in GIST882, and by PKC412 treatment in the imatinibresistant GIST48 cell line. The staurosporine derivative PKC412 was originally identified as an inhibitor of protein kinase C (PKC) and subsequently shown to inhibit other kinases including VEGFR2, PDGFR and KIT (Fabbro et al., 2000) , with activity in some imatinib-resistant GIST mutations (Debiec-Rychter et al., 2005) . The phosphotyrosine eluate studies confirmed the immunoprecipitation assays (Figures 1  and 3) , showing imatinib/PKC412 inhibition of KIT, PDGFRA and PI3-K ( Figure 5) . Comparisons between total cell lysates and phosphotyrosine purifications ( Figure 5) showed that KIT, PI3-K (regulatory and catalytic subunits), SHC and GRB2 were strongly tyrosine phosphorylated in a KIT-dependent manner in both GIST882 and GIST48 cell lines. These findings are consistent with KIT oncogenic activation of the RAS/RAF/MAPK and PI3-K/AKT pathways, which are regulated by activation of GRB2/SHC and PI3-K, respectively (Tauchi et al., 1994; Blume-Jensen et al., 1998) . Recruitment of GRB2 and SHC adaptor proteins to RTK-derived oncogenes has been shown to be sufficient for morphological cell transformation and experimental metastases (Saucier et al., 2002 ), whereas Figure 6 (a-c) Cell density effects on KIT/PDGFR-dependent activation of kinase signaling proteins in GIST48, with and without KIT/PDGFR inhibition by PKC412. As in Figure 5 , total cell lysates (lanes 1 and 4 in a and b) and immunoaffinity-purified tyrosinephosphorylated proteins (lanes 2 and 3 in a and b) were immunostained to evaluate KIT-dependent activation of various signaling proteins. Tyrosine phosphorylation was evaluated in cells harvested from 100% confluent (images from Figure 5 ) vs 75% confluent cultures (a and b). PI3-K p85, FAK and Paxillin were more strongly phosphorylated in 75% confluent cultures, PI3-K p110a and JAK1 were more strongly phosphorylated in 100% confluent cultures. In the 75% confluent cultures, the accentuated phosphorylation of PI3-K p85 and paxillin, but not FAK, is KIT dependent. STAT, JAK2 and HSP90 phosphorylation were unaffected by culture confluence. Increased FAK and paxillin phosphorylation, in subconfluent cultures, was confirmed in GIST48 total cell lysates immunostained with antibodies to phospho-FAK and phospho-paxillin (c). These studies showed that FAK and paxillin tyrosine phosphorylation were reduced in 100% confluent cultures, compared to the subconfluent cultures.
PI3-K appears to play a particularly crucial role in tyrosine kinase oncoprotein signaling (Sordella et al., 2004) . Therefore, our findings suggest that PI3-K, GRB2 and SHC might serve as alternate therapeutic targets, whose inhibition could be beneficial in GIST patients resistant to imatinib.
Our present studies corroborate previous reports that STAT activation, in GISTs, is relatively weak and only partially dependent on the activated KIT oncoprotein (Duensing et al., 2004b) . This situation differs from the KIT kinase-domain mutants in mast cell disease, where STAT is activated strongly and crucial to KIT transforming activity (Ning et al., 2001) . In addition, whereas STAT activation is regulated by cell density in a carcinoma model (Vultur et al., 2004) , being more strongly activated in subconfluent cultures than in confluent cultures, we did not observe marked increase in STAT activation in subconfluent GIST cultures.
The involvement of cell adhesion proteins has not been evaluated previously in GISTs, and our studies show that the FAK and paxillin adhesion-related proteins are activated in a cell density-dependent manner. That is, activation of both FAK and paxillin activation was strongest in subconfluent, actively proliferating, cultures. FAK activation was KIT independent in both confluent and subconfluent cultures (Figures 5 and 6 ), whereas paxillin activation was KIT independent in confluent cultures and partially KIT dependent in subconfluent cultures. These findings suggest that imatinib impact on adhesion proteins, in clinical GISTs, might vary in different parts of the same tumor, depending on the local architecture and cell density. Notably, the KIT-independent nature of FAK activation, in these GIST models, suggests that FAK therapeutic inhibition might provide clinical synergies for KIT inhibition by imatinib.
The novel PKC family member, PKCy, is an intriguing biomarker in GIST, given its narrow range of expression in normal cells, and preliminary evidence 2 and 4) . In each panel, lanes 1 and 2 are total cell lysates, whereas lanes 3 and 4 are immunoprecipitates evaluating kinase activation. Immunostains of the PY99 (Santa Cruz, sc-7020) immunoprecipitates (a) showed that KIT shRNA infections reduced the expression of total and phospho-KIT to 50% of control levels, resulting in 35, 51 and 52% reductions in tyrosine-phosphorylated PI3-K p85, CBL and PDGFRA, respectively. Protein expression quantitation was performed using a FUJI LAS1000 þ digital capture system. Similarly, phosphotyrosine immunostaining of PDGFRA immunoprecipitates (b) demonstrated 60% reduction in PDGFRA phosphorylation, after KIT shRNA knockdown.
for a positive regulatory role in KIT oncogenic signaling in GIST (Duensing et al., 2004a) . We show, for the first time, that PKCy associates with KIT oncoproteins in GIST cell lines (Figure 3) , and is tyrosine phosphorylated in a KIT-dependent manner, particularly in subconfluent cells (Figures 5 and 6 ). Strong PKCy expression has been reported -in adult tissues -only in T cells and ICC, and in the leukemias and GISTs that derive, respectively, from these cell lineages. Therefore, it is possible that PKCy inhibition might be a minimally toxic and highly effective therapy for GIST. Our preliminary studies with PKCy inactivation or RNAi knockdown (Hubert, Ou and Fletcher, unpublished) do indeed suggest that PKCy expression and activation are crucial to GIST cell survival and proliferation.
Materials and methods
Reagents
Antibodies for immunoprecipitation and immunoblotting are described in the Supplementary methods.
Tissue specimens and cell lines GIST tissue specimens and cell lines are described in the Supplementary methods.
Functional studies
Biochemical correlates for KIT inhibition were evaluated in GIST882 and GIST48 cells after incubation for 4 h in serumfree media with 2 mM imatinib and 1 mM PKC412 (provided by Novartis Pharma, Basel, Switzerland), respectively. 0 ] oligomers into the AgeI and EcoRI sites of a pLKO.1puro lentiviral vector. Lentivirus was produced by cotransfecting pLKO.1puro empty vector or pLKO.1puro-KIT (shRNA), pCMVDR8.91 and pMD.G helper virus packaging plasmids (at a 10:10:1 ratio) into 293T cells. These transfections were performed using lipofectamine and PLUS reagent, and lentivirus supernatants were harvested at 24, 36, 48 and 60 h. Viral titers were determined in GIST882 cells, according to a protocol from Invitrogen (Carlsbad, CA, USA). GIST882 cells were infected, in the presence of 8 mg/ml of polybrene, and were then lysed for immunoprecipitation and western blot analysis after 20 days of selection with 2.5 mg/ml puromycin.
Immunoprecipitation and western blot analysis Immunoprecipitation and immunoblotting methods were essentially as described, and are detailed in the Supplementary methods. The chemiluminescence signals were captured and quantified using a FUJI LAS1000plus system with Science Lab 2001 ImageGauge 4.0 software (Fujifilm Medical Systems, Stamford, CT, USA).
Phosphotyrosine affinity purification
The phosphotyrosine fraction was isolated from GIST cells using a minicolumn loaded with 1 ml of anti-phosphotyrosinesepharose beads (Zymed, South San Francisco, CA, USA). The anti-phosphotyrosine affinity columns were first washed ten times with phosphate-buffered saline containing 0.02% sodium azide followed by ten washes with cell lysis buffer. The columns were then incubated at 41C overnight with 10 mg of GIST protein lysate, washed seven times with lysis buffer, and the bound tyrosine-phosphorylated proteins were then eluted by loading the column ten times with 1 ml of 100 mM phenylphosphate. The phosphotyrosine protein eluates were dialysed to remove the phenylphosphate, then evaluated by immunoblotting, using 10% of the eluates per gel lane.
